Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Kite Pharma (KITE) Stock Price

Press coverage about Kite Pharma (NASDAQ:KITE) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kite Pharma earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.9675392385732 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Kite Pharma stock remained flat at $$179.79 during mid-day trading on Friday. Kite Pharma has a 1-year low of $39.82 and a 1-year high of $179.99.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-kite-pharma-kite-stock-price.html.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply